Antibiotics impair immune checkpoint inhibitor effectiveness in hispanic patients with non-small cell lung cancer (AB-CLICaP)

Vista sencilla de ítem
dc.contributor.authorRuiz-Patinõ, Alejandro
dc.contributor.authorBarrón-Barrón, Feliciano
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorCorrales, Luis
dc.contributor.authorMas, Luis
dc.contributor.authorMartín, Claudio Marcelo
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorRecondo, Gonzalo
dc.contributor.authorRicaurte, Luisa María
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez, July F.
dc.contributor.authorSotelo-Rodríguez, Diana Carolina
dc.contributor.authorViola Muñoz, Lucía
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorCarranza, Hernán
dc.contributor.authorOtero, Jorge Miguel
dc.contributor.authorPino, Luis Eduardo
dc.contributor.authorRolfo, Christian
dc.contributor.authorRosell, Rafael Costa
dc.contributor.authorArrieta, Oscar
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidSotelo-Rodríguez, Diana Carolina [0000-0002-7763-4760]
dc.contributor.orcidViola Muñoz, Lucía [0000-0002-1647-2884]
dc.date.accessioned2020-08-04T22:22:41Z
dc.date.available2020-08-04T22:22:41Z
dc.description.abstractenglishBackground The intestinal microbiota is an important factor in modulating immune‐mediated tumor cell destruction. Alterations in the microbiome composition have been linked to reduced efficacy of immune checkpoint inhibitor (ICI) therapies. Therefore, antibiotic treatment (ATB), which modifies the diversity of the gut bacteria populations, could lead to a reduced efficacy of ICI treatments. Methods This was a retrospective cohort study. Patients with advanced non‐small cell lung cancer (NSCLC) treated with anti‐programmed cell death ligand‐1 (PD‐L1) alone, or in combination in three different countries in Latin America were included. After identification, patients were placed into three groups: Non‐ATB exposed (no‐ATB), exposed within 30 days of the first dose of ICI (pre‐ICI ATB) and patients receiving ATB concomitantly with ICI (ICI‐ATB). Progression‐free survival (PFS), overall survival (OS) and response rates to treatment with ICI were assessed. Results A total of 140 patients were included, of which 32 patients (23%) received ATB treatment. The most common ATB types were fluoroquinolones and B‐lactams. No differences in survival according to antibiotic type were identified. Median OS in patients not exposed to ATB was 40.6 months (95% CI: 32–67.7), compared with 20.3 months (95% CI: 12.1‐non‐reached [NR]) for patients with pre‐ICI ATB treatment and 24.7 months (95% CI: 13‐NR) for patients treated with ATB concomitantly with ICI. There were no significant differences in terms of PFS, or response rates across all treatment groups. Conclusions Antibiotic treatment was associated with reduced OS in Hispanic patients with NSCLC treated with ICIs.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1111/1759-7714.13573
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1759-7714
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3676
dc.language.isoeng
dc.publisherWiley-Blackwellspa
dc.publisher.journalThoracic cancerspa
dc.relation.ispartofseriesThoracic cancer, 1759-7714, 2020spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13573
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-07-24
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordsAntibioticsspa
dc.subject.keywordsImunotherapyspa
dc.subject.keywordsLung cancerspa
dc.titleAntibiotics impair immune checkpoint inhibitor effectiveness in hispanic patients with non-small cell lung cancer (AB-CLICaP)spa
dc.title.translatedAntibiotics impair immune checkpoint inhibitor effectiveness in hispanic patients with non-small cell lung cancer (AB-CLICaP)spa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Alejandro Ruiz-Patiño, Feliciano Barrón, Andrés F. Cardona_2020.pdf
Tamaño:
495.09 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos